Abbott

ID NOW™ RSV — MOLECULAR. IN MINUTES.™

THE FASTEST MOLECULAR RSV TEST[1]

TRUSTED RESULTS DURING THE PATIENT ENCOUNTER

ID NOW™ RSV test provides highly sensitive molecular results in **13 minutes or less.**

- 25% higher sensitivity than rapid antigen tests[2]
- Allows timely isolation and appropriate treatment[3] in those most impacted by RSV - pediatrics and elderly patients
- Aligns with diagnostic stewardship initiatives with a test specifically for RSV
- CLIA-waived intuitive procedure allows for easy standardization across care settings

RAPID AND ACTIONABLE RSV TESTING

THE FASTEST MOLECULAR TEST FOR RSV

Generate actionable and reliable molecular test results during the patient encounter with the ID NOW™ RSV test. Results are available in minutes for timely and efficient clinical management and infection control decisions.

No other molecular platform provides RSV results faster than ID NOW.™[1]

POINT-OF-CARE SETTINGS ARE **TIME SENSITIVE**

91% of Family Physicians

96% of Pediatricians

100% of ED Clinicians

→ Spend **≤24 minutes** with the patient[4]

UNCOMPROMISED MOLECULAR PERFORMANCE

ISOLATE AND TREAT WITH HIGHER CONFIDENCE

Molecular technologies – isothermal and PCR – provide highly sensitive test results. The ID NOW™ platform uses isothermal technology to provide molecular results faster than PCR with equivalent detection of RSV.[5]

- Detect more true positives with 25% higher sensitivity than rapid antigen tests[2]
- Differentiate RSV from Influenza A & B with a single swab using VTM**



* Direct swab and VTM
**VTM, viral transport media and nasopharyngeal swab required. The ID NOW™ RSV test and Influenza A & B 2 test are sold separately.

RSV DETECTION AT THE POINT OF CARE

IMPROVE QUALITY OF CARE AND PATIENT OUTCOMES

RSV is the leading cause of bronchiolitis and a significant contributor to morbidity and mortality in infants, the elderly and immunocompromised individuals.[6] Patients with RSV also require higher levels of care and longer hospitalizations.[7]

Vaccines are now available to reduce the risk of severe disease,[8,9] and therapies are in development. Rapid, accurate RSV testing enables timely clinical decisions that impact care.[3,10]

DIFFERENTIALLY DIAGNOSE RESPIRATORY INFECTIONS[6]

Decrease suspicion of bacterial infection[6]

Reduce inappropriate antibiotic use[3]

Shorten ED length of stay[10]

APPROPRIATELY ISOLATE PATIENTS

Reduce healthcare-associated infections[11]

Lower risk of community transmission, particularly in daycare or elderly populations[11]

ID NOW™ RAPID MOLECULAR PLATFORM

CLIA WAIVED TO STANDARDIZE USE ACROSS CARE SETTINGS

- Minimal training with on-screen video-guided operation
- No complex sample handling or manual pipetting required
- Room temperature storage — run tests on demand, right out of the box
- Robust on-board software, and POC Link connectivity tool to enable streamlined remote software updates for ID NOW™ Instruments

ID NOW™ RESPIRATORY ASSAY MENU

COVID-19	Influenza A & B	Strep A	RSV
6–12 mins	5–13 mins[12]	2–6 mins[13]	≤ 13 mins

THE POINT. IS CARE.

PRODUCT NAME	PRODUCT CODE	CPT® CODE†	MEDICARE RATE††
ID NOW™ RSV TEST KIT	435-000	87634	$70.20
ID NOW™ RSV CONTROL SWAB KIT	435-080		
ID NOW™ INSTRUMENT	NAT-024		

Each test kit contains 24 tests, collection swabs and controls.

CONTACT YOUR LOCAL ABBOTT REPRESENTATIVE
OR VISIT **GLOBALPOINTOFCARE.ABBOTT**

†Providers with a CLIA Certificate of Waiver should use the QW modifier when appropriate.
††2024 Medicare Clinical Laboratory Fee Schedule.
Current Procedural Terminology (CPT®) code information and current Medicare allowable reimbursement rates available at www.codemap.com/abbottpoc. As a courtesy to its customers, Abbott provides the most accurate and up-to-date information available, but it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage of payment for our products or reimburse customers for claims that are denied by third party payors.

1. ID NOW. Rapid Test Times to Result Analysis (v1.0). **2.** Chartrand C, Tremblay N, Renaud C, et al. Diagnostic Accuracy of Rapid Antigen Detection Tests for Respiratory Syncytial Virus Infection: Systematic Review and Meta-analysis. J Clin Microbiol. 2015 Dec;53(12):3738-49. **3.** Nardi S, Carolis L, Iannini R, et al. Usefulness of rapid molecular tests in pediatric respiratory tract infections. Ital J Pediatr. 2022 Feb 3;48(1):21. **4.** Medscape. Physician Compensation Report 2017, accessed May 2, 2023. https://www.medscape.com/sites/public/physician-comp/2017. **5.** Bernstein DI, Mejias A, Rath B, et al. Summarizing Study Characteristics and Diagnostic Performance of Commercially Available Tests for Respiratory Syncytial Virus: A Scoping Literature Review in the COVID-19 Era. J Appl Lab Med. 2023 Mar 6;8(2):353-371. **6.** Barr R, Green CA, Sande CJ, et al. Respiratory syncytial virus: diagnosis, prevention and management. Ther Adv Infect Dis. 2019 Jul 29;6:2049936119865798. **7.** Walsh E, Lee N, Sander I, et al. RSV-associated hospitalization in adults in the USA: A retrospective chart review investigating burden, management strategies, and outcomes. Health Sci Rep. 2022 Apr 14;5(3):e556. **8.** CDC. Frequently Asked Questions About RSV Vaccine for Adults. https://www.cdc.gov/vaccines/vpd/rsv/hcp/older-adults-faqs. html, updated Aug 30, 2023. **9.** FDA. FDA Approves New Drug to Prevent RSV in Babies and Toddlers. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers, July 17, 2023. **10.** Rogan DT, Kochar MS, Yang S, et al. Impact of rapid molecular respiratory virus testing on real-time decision making in a pediatric emergency department. J Mol Diagn. 2017;19(3):460-7. **11.** Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474-502. **12.** Abbott. Data on file. ID NOW™ Influenza A & B 2 clinical trial data. **13.** Abbott. Data on file. ID NOW™ Strep A 2 clinical trial data.

Abbott